These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The current landscape and unmet needs in multiple sclerosis. Markowitz CE Am J Manag Care; 2010 Sep; 16(8 Suppl):S211-8. PubMed ID: 20873945 [TBL] [Abstract][Full Text] [Related]
25. [Current state of research on multiple sclerosis]. Lubina-Dabrowska N; Stepień A; Chalimoniuk M Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821 [TBL] [Abstract][Full Text] [Related]
27. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study. Webb UH J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303 [TBL] [Abstract][Full Text] [Related]
28. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis]. Cazzato G; Antonello RM; Zorzon M; Torre P; Zivadinov R; Moretti R; Bragadin LM; De Masi R; Nasuelli D Recenti Prog Med; 1999 Oct; 90(10):538-44. PubMed ID: 10592740 [TBL] [Abstract][Full Text] [Related]
29. Approaches to neuroprotective strategies in multiple sclerosis. Tselis A; Khan OA; Lisak RP Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779 [TBL] [Abstract][Full Text] [Related]
30. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Lage MJ; Castelli-Haley J; Oleen-Burkey MA Work; 2006; 27(2):143-51. PubMed ID: 16971761 [TBL] [Abstract][Full Text] [Related]
31. [Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple sclerosis]. Vermeulen M Ned Tijdschr Geneeskd; 2007 Apr; 151(15):850-1. PubMed ID: 17472114 [TBL] [Abstract][Full Text] [Related]
32. [The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments]. Moreira MA; Lana-Peixoto MA; Callegaro D; Haussen SR; Gama PD; Gabbai AA; Rocha FC; Lino AM; Arq Neuropsiquiatr; 2002 Sep; 60(3-B):875-80. PubMed ID: 12364966 [TBL] [Abstract][Full Text] [Related]
34. Current therapeutic recommendations in multiple sclerosis. Berger T J Neurol Sci; 2009 Dec; 287 Suppl 1():S37-45. PubMed ID: 20106347 [TBL] [Abstract][Full Text] [Related]
35. [Diagnostics and drug therapy of multiple sclerosis]. Suomen Neurologinen Yhdistys ry Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889 [No Abstract] [Full Text] [Related]
36. Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis. Mattson DH Semin Neurol; 2002 Mar; 22(1):17-25. PubMed ID: 12170390 [TBL] [Abstract][Full Text] [Related]
37. Early treatment. Comi G Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191 [TBL] [Abstract][Full Text] [Related]
38. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS. Pöllmann W; Erasmus LP; Feneberg W; Straube A Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675 [TBL] [Abstract][Full Text] [Related]